Xiamen Amoytop Biotech 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Li Sun

최고 경영자

CN¥2.2m

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	10.8%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 26% Jump Shows Its Popularity With Investors

Sep 19

Investors Appear Satisfied With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Prospects As Shares Rocket 26%

Sep 19

Is There An Opportunity With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 50% Undervaluation?

Jun 12

Xiamen Amoytop Biotech (SHSE:688278) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 04

Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Share Price Could Signal Some Risk

Mar 25

CEO

Li Sun (58 yo)

no data

테뉴어

CN¥2,196,500

보상

Mr. Li Sun is Chairman & GM of Xiamen Amoytop Biotech Co., Ltd. He was Director and General Manager of Xiamen Amoytop Biotech Co., Ltd.

Xiamen Amoytop Biotech 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Xiamen Amoytop Biotech Co., Ltd., Annual General Meeting, Apr 29, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Now 20% undervalued

Third quarter 2024 earnings released: EPS: CN¥0.61 (vs CN¥0.41 in 3Q 2023)

Xiamen Amoytop Biotech Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 19%

Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 26% Jump Shows Its Popularity With Investors

Investors Appear Satisfied With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Prospects As Shares Rocket 26%

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: CN¥0.43 (vs CN¥0.29 in 2Q 2023)

Xiamen Amoytop Biotech Co., Ltd. to Report First Half, 2024 Results on Aug 22, 2024

Is There An Opportunity With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 50% Undervaluation?

Xiamen Amoytop Biotech Co., Ltd., Annual General Meeting, Apr 29, 2024

Xiamen Amoytop Biotech (SHSE:688278) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Xiamen Amoytop Biotech Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Share Price Could Signal Some Risk

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 19%

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 19%

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.16 in 3Q 2022)

Investor sentiment improves as stock rises 16%

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.19 in 2Q 2022)

Investor sentiment deteriorates as stock falls 17%

Xiamen Amoytop Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

First quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.14 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.71 (vs CN¥0.45 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.13 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.10 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.074 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.06 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.06 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.29 (vs CN¥0.18 in FY 2019)

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: EPS CN¥0.29 (vs CN¥0.18 in FY 2019)

New 90-day low: CN¥33.40

New 90-day low: CN¥42.70

New 90-day low: CN¥47.20

New 90-day low - CN¥47.35

Xiamen Amoytop Biotech Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

CEO

테뉴어

보상